Biopharmaceuticals Market Growth and Key Manufacturers (2021 – 2030)
The global biopharmaceuticals market was valued at USD 333.1 billion in 2022 and is expected to exceed USD 856.1 billion by 2030. This growth reflects a strong compound annual growth rate (CAGR) of 12.5% during the forecast period from 2021 to 2030.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5012
Biopharmaceuticals: Advanced Medicines from Living Organisms
Biopharmaceuticals, often called “biologics,” are complex medicines derived from living cells or organisms. These advanced drugs are typically created using modern biotechnological methods. By extracting proteins and nucleic acids directly from biological sources, biopharmaceuticals play a vital role in medical treatments.
Some biopharmaceuticals are produced using genetically modified plants and animals, known as transgenic organisms. While this innovative technology holds promise, it remains in the experimental phase and continues to be a topic of ongoing research and debate.
Leading Companies in the Biopharmaceuticals Market
The biopharmaceuticals market is driven by several global players renowned for their innovation and extensive product portfolios:
- Abbott Laboratories: A leader in healthcare, Abbott develops biopharmaceutical solutions across various therapeutic areas, including metabolic and infectious diseases.
- Amgen, Inc.: A pioneer in biotechnology, Amgen focuses on innovative therapies for serious illnesses, particularly in oncology, inflammation, and cardiovascular diseases.
- Biogen, Inc.: Known for its advancements in neuroscience, Biogen specializes in treatments for neurological and neurodegenerative conditions like multiple sclerosis and Alzheimer’s disease.
- Eli Lilly and Company: A global pharmaceutical company, Lilly is at the forefront of diabetes management, oncology, and immunology treatments.
- F. Hoffmann-La Roche, Ltd.: Roche is a prominent player in oncology, immunology, and rare diseases, leveraging its expertise in biotechnology and diagnostics.
- Johnson & Johnson: With a diverse healthcare portfolio, J&J develops biopharmaceutical products targeting infectious diseases, oncology, and immunology.
- Merck & Co., Inc.: Renowned for its innovative therapies, Merck addresses areas like oncology, infectious diseases, and vaccine development.
- Novo Nordisk A/S: A global leader in diabetes care, Novo Nordisk also develops biopharmaceuticals for hormone replacement therapies and hemophilia.
- Pfizer, Inc.: A key player in the biopharmaceutical market, Pfizer offers a wide range of therapies, including vaccines, oncology, and rare diseases.
- Sanofi: Specializing in vaccines and specialty care, Sanofi is a leader in treatments for diabetes, cardiovascular diseases, and rare conditions.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/biopharmaceuticals-market-is-rising-rapidly
Access exclusive insight now @ https://www.towardshealthcare.com/price/5012
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
